Larimar Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Larimar Therapeutics reports significant progress in its nomlabofusp clinical program for Friedreich's ataxia, including positive OL study data and key regulatory designations, while securing $107.6 million in new funding.
NASDAQ
10-K: Larimar Therapeutics Reports Positive Data, Targets BLA Submission for Nomlabofusp by Year-End 2025
Larimar Therapeutics advances nomlabofusp, a potential treatment for Friedreich's ataxia, with positive clinical data and a targeted BLA submission by the end of 2025.
NASDAQ
Larimar Therapeutics' 10-K filing details a non-qualified stock option grant, updates on clinical trials for nomlabofusp, and outlines financial strategies for the company's future.